Advertisement

Regulatory Considerations for Early Clinical Development of Drugs for Diabetes, Obesity, and Cardiometabolic Disorders

  • G. Alexander Fleming
Chapter

Abstract

Advancing therapeutic discoveries through early clinical studies benefits from a working knowledge of regulatory history, practices, provisions, procedures, and controversies. This chapter aims to supplement readily available published and web-based resources that describe regulatory expectations and requirements. Though the Food and Drug Administration is emphasized, the importance of the European Medicines Agency (EMA) and other major authorities is acknowledged. Some relevant differences between EMA and the Food and Drug Administration (FDA) are discussed. With emphasis on early studies, selected regulatory considerations are presented for developing diabetes, anti-obesity, and lipid-lowering therapies toward existing therapeutic indications. Novel therapeutic indications that have reasonable prospects for approval are also described. Interpretations and preferences expressed reflect the author’s experience as an endocrinologist and an FDA representative, educator, and reviewer responsible for approval of the first statin and insulin analog, metformin, and other metabolic products.

Keywords

European Medicines Agency (EMA) Food and Drug Administration (FDA) Good Clinical Practice (GCP) International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Investigational New Drug (IND) Institutional Review Boards (IRB) Medical Dictionary for Regulatory Activities (MedDRA) New Drug Application (NDA) Orphan drug Study design 

References

  1. 1.
    Significant Dates in U.S. Food and Drug Law History. http://www.fda.gov/AboutFDA/WhatWeDo/History/Milestones/ucm128305.htm. Accessed 12 Jan 2014.
  2. 2.
    European Medicines Agency: Human medicines regulatory information. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/landing/human_medicines_regulatory.jsp&mid=WC0b01ac058001ff89. Accessed 12 Jan 2014.
  3. 3.
    Rahalkar H. Historical overview of pharmaceutical industry and drug regulatory affairs. Pharmaceut Reg Aff. 2012;S11:002.Google Scholar
  4. 4.
    ICH Topic E6 (R1) Guideline for Good Clinical Practice. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002874.pdf. Accessed 19 Sept 2014.
  5. 5.
  6. 6.
    Hiatt WR, Kaul S, Smith RJ. The cardiovascular safety of diabetes drugs—insights from the rosiglitazone experience. N Engl J Med. 2013;369:1285–128.PubMedCrossRefGoogle Scholar
  7. 7.
    Marris E. Diabetes drugs under scrutiny in a post-Vioxx world. Nat Rev Drug Discov. 2007;6:505–6.PubMedCrossRefGoogle Scholar
  8. 8.
    Roy ASA. Stifling new cures: the true cost of lengthy clinical drug trials. http://www.manhattan-institute.org/html/fda_05.htm. Accessed 20 Jan 2014.
  9. 9.
    About ICH: History. http://www.ich.org/about/history.html. Accessed 31 Jan 2014.
  10. 10.
    Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The cardiac arrhythmia suppression trial. N Engl J Med. 1991;324:781–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Brown NJ, Vaughan DE. Cardiovascular drugs: angiotensin-converting enzyme inhibitors. Circulation.1998;97:1411–20.PubMedCrossRefGoogle Scholar
  12. 12.
    Lambers Heerspink HJ, Perkovic V, de Zeeuw D. Is doubling of serum creatinine a valid clinical ‘hard’ endpoint in clinical nephrology trials? Nephron Clin Pract. 2011;119:c195–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Jiang S, Park C, Barner C. Ranibizumab, VEG-F inhibitor Ranibizumab for age-related macular degeneration: a meta-analysis of dose effects and comparison with no anti-VEGF treatment and bevacizumab. J Clin Pharm Ther. 2014;39:234–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Chalk C, Benstead TJ, Moore F. Aldose reductase inhibitors for the treatment of diabetic polyneuropathy. Cochrane Database Syst Rev. 2007. (4):CD004572. doi: 10.1002/14651858.CD004572.pub2.
  15. 15.
    Guidance for Industry–Diabetes Mellitus: Developing Drugs and Therapeutic Biologics for Treatment and Prevention. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071624.pdf. Accessed 20 May 2014.
  16. 16.
    Tardif J-C, Heinonen T, Orloff D, Libby P. Vascular biomarkers and surrogates in cardiovascular disease. Circulation. 2006;113:2936–42.PubMedCrossRefGoogle Scholar
  17. 17.
    Rosen CJ. Revisiting the rosiglitazone story—lessons learned. N Engl J Med. 2010;363:803–6.PubMedCrossRefGoogle Scholar
  18. 18.
    Guidance for Industry Diabetes Mellitus — Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071627.pdf. Accessed 20 May 2014.
  19. 19.
    Alldredge BK, Corelli RL, Ernst ME, Guglielmo BJ, Jacobson PA, Kradjan WA, Williams BR. In: Koda-Kimble & young’s applied therapeutics: the clinical use of drugs. Published 10th ed. Lippincott Williams & Wilkins; 2012. p. 252–67.Google Scholar
  20. 20.
    Psaty BM, Lumley T. Surrogate end points and FDA approval: a tale of 2 lipid-altering drugs. JAMA. 2008;299:1474–6.PubMedCrossRefGoogle Scholar
  21. 21.
    Institute for Quality and Efficiency in Health Care (2011, September 14). Elevated cholesterol levels: no clear benefit of ezetimibe, report suggests. ScienceDaily. Retrieved 9 Jun 2014 from www.sciencedaily.com/releases/2011/09/110914110109.htm.
  22. 22.
    Hirshberg B, Raz I. Impact of the U.S. food and drug administration cardiovascular assessment requirements on the development of novel antidiabetes drugs. Diabetes Care. 2011;34:s101–6.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    What does FDA regulate? http://www.fda.gov/AboutFDA/Transparency/Basics/ucm194879.htm. Accessed 10 Jun 2014.
  24. 24.
    FDA Fundamentals. http://www.fda.gov/AboutFDA/Transparency/Basics/ucm192695.htm. Accessed 20 May 2014.
  25. 25.
  26. 26.
    Medical Foods Guidance Documents and Regulatory Information. http://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/MedicalFoods/default.htm. Accessed 31 Jan 2014.
  27. 27.
    Degnan FH. The US food and drug administration and probiotics: regulatory categorization. Clin Infect Dis. 2008;46 Suppl 2:S133–6. doi: 10.1086/523324.PubMedCrossRefGoogle Scholar
  28. 28.
    Draft Guidance for Industry: Frequently Asked Questions About Medical Foods; Second Edition. http://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/MedicalFoods/ucm054048.htm. Accessed 31 Jan 2014.
  29. 29.
    Guidance for Industry: End-of-Phase 2A Meetings. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm079690.pdf. Retrieved January 2014.
  30. 30.
    Guidance for Industry: Formal Meetings Between the FDA and Sponsors or Applicants. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM153222.pdf. Retrieved January 2014.
  31. 31.
    Guidance for Industry, Investigators, and Reviewers: Exploratory IND Studies. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM078933.pdf.
  32. 32.
    Guidance for Clinical Investigators, Sponsors, and IRBs: Investigational New Drug Applications (INDs) — Determining Whether Human Research Studies Can Be Conducted Without an IND. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm229175.pdf.
  33. 33.
    Guidance for Industry: Content and Format of Investigational New Drug Applications (INDs) for Phase 1 Studies of Drugs, Including Well-Characterized, Therapeutic, Biotechnology-derived Products. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM074980.pdf.
  34. 34.
    Code of Federal Regulations Title 21 Chapter I—Food and Drug Administration Department of Health And Human Services Subchapter A—General Part 56 Institutional Review Boards. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=56.
  35. 35.
    Engelberg AB, Kesselheim AS, Avorn J. Balancing innovation, access, and profits – market exclusivity for biologics. N Engl J Med. 2009;361:1917–9.PubMedCrossRefGoogle Scholar
  36. 36.
    Meekings KN, Williams CS, Arrowsmith JE. Orphan drug development: an economically viable strategy for biopharma R&D. Drug Discov Today. 2012;17(13–14):660–4.PubMedCrossRefGoogle Scholar
  37. 37.
  38. 38.
    Shani S, Yahalom Z. Legal and regulatory aspects of orphan drugs. Pediatr Endocrinol. 2013;11 Suppl 1:110–5.Google Scholar
  39. 39.
    Pastores GM, Gupta P. Orphan drug development. Pediatr Endocrinol. 2013;11 Suppl 1:64–7.Google Scholar
  40. 40.
    Wizemann T, Robinson S, and Giffin R. 7 strategies for facilitating clinical trials breakthrough business models: drug development for rare and neglected diseases and individualized therapies. Workshop Summary. 2008;82–97.Google Scholar
  41. 41.
    FDA approves Myalept to treat rare metabolic disease. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm387060.htm.
  42. 42.
    Chan JL, Lutz K, Cochran E, Huang W, Peters Y, Weyer C, Gorden P. Clinical effects of long-term metreleptin treatment in patients with lipodystrophy. Endocr Pract. 2011;17(6):922–32.PubMedCentralPubMedCrossRefGoogle Scholar
  43. 43.
  44. 44.
    Fast Track, Breakthrough Therapy, Accelerated Approval and Priority Review. http://www.fda.gov/forconsumers/byaudience/forpatientadvocates/speedingaccesstoimportantnewtherapies/ucm128291.htm.
  45. 45.
    Treatment of recent-onset type 1 diabetic patients with DiaPep277: results of a double-blind, placebo-controlled, randomized phase 3 trial. Raz I, Ziegler AG, Linn T, Schernthaner G, Bonnici F, Distiller LA, Giordano C, Giorgino F, de Vries L, Mauricio D, Procházka V, Wainstein J, Elias D, Avron A, Tamir M, Eren R, Peled D, Dagan S, Cohen IR, Pozzilli P; DIA-AID 1 Writing Group. Diabetes Care. 2014; 37:1392–400.Google Scholar
  46. 46.
    Fleming GA. Regulatory and policy issues for T1DM immunotherapy. Human Vaccines. 7:1, 1–6; January 2011. http://investors.hyperiontx.com/releases.cfm. Accessed 19 September 2014.
  47. 47.
    Guidance for Industry Diabetes Mellitus: Developing Drugs and Therapeutic Biologics for Treatment and Prevention. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071624.pdf.
  48. 48.
    Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362(18):1675–85.PubMedCentralPubMedCrossRefGoogle Scholar
  49. 49.
    Intercept Announces NASH Primary Endpoint Met: FLINT Trial Stopped Early for Efficacy Based on Highly Statistically Significant Improvement in Liver Histology. http://ir.interceptpharma.com/releasedetail.cfm?ReleaseID=818119. Accessed 20 May 2014.
  50. 50.
    Galmed Pharmaceuticals: Aramchol — A first-in-class drug for NASH. http://www.galmedpharma.com/products-2/aramchol/. Accessed 20 May 2014.
  51. 51.
  52. 52.
    Fountaine RJ, Taylor AE, Mancuso JP, Greenway FL, Byerley LO, Smith SR, Most MM, Fryburg DA. Increased food intake and energy expenditure following administration of olanzapine to healthy men. Obesity (Silver Spring). 2010;18(8):1646–51.CrossRefGoogle Scholar
  53. 53.
    Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. JAMA. 2014;311(1):74–86.Google Scholar
  54. 54.
    Guidance for Industry: Developing Products for Weight Management. http://www.fda.gov/downloads/Drugs/Guidances/ucm071612.pdf. Accessed 6 Jun 2014.
  55. 55.
    Ceriello A. Postprandial hyperglycemia and cardiovascular disease: is the HEART2D study the answer? Diabetes Care. 2009;32(3):521–2.Google Scholar
  56. 56.
    Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care. 2003;26(3):881–5.PubMedCrossRefGoogle Scholar
  57. 57.
    Riddle M, Umpierrez G, DiGenio A, Zhou R, Rosenstock J. Contributions of basal and postprandial hyperglycemia over a wide range of A1c levels before and after treatment intensification in type 2 diabetes. Diabetes Care. 2011;34(12):2508–14.PubMedCentralPubMedCrossRefGoogle Scholar
  58. 58.
    Rosenson RS, Underberg JA. Systematic review: evaluating the effect of lipid-lowering therapy on lipoprotein and lipid values. Cardiovasc Drugs Ther. 2013;27:465–79.PubMedCentralPubMedCrossRefGoogle Scholar
  59. 59.
    Guideline for Industry: The Extent of Population Exposure to Assess Clinical Safety: For Drugs Intended for Longterm Treatment of Non-Life-Threatening Conditions. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073083.pdf. Accessed 6 Jun 2014.
  60. 60.
    Cosentino G, Conrad AO, Uwaifo GI. Phentermine and topiramate for the management of obesity: a review. Drug Des Devel Ther. 2013;7:267–78.PubMedCentralPubMedGoogle Scholar
  61. 61.
    Ornellas T, Chavez B. Naltrexone SR/bupropion SR (Contrave): a new approach to weight loss in obese adults. Proc Natl Acad Sci U S A. 2011;36:255–62.Google Scholar
  62. 62.
  63. 63.
  64. 64.
  65. 65.
    Rodgers RJ, Tschöp MH, Wilding JP. Anti-obesity drugs: past, present and future. Dis Model Mech. 2012;5(5):621–6.PubMedCentralPubMedCrossRefGoogle Scholar
  66. 66.
    Colombo IO, Ferretti VV, Ferraris C, Trentani C, Vinai P, Villani S, Tagliabue A. Is drop-out from obesity treatment a predictable and preventable event? Nut J. 2014;13:13.CrossRefGoogle Scholar
  67. 67.
    The prevention and treatment of missing data in clinical trials. National Research Council. (U.S.). Panel on handling missing data in clinical trials.; National Research Council (U.S.). Committee on National Statistics.; National Academies Press (U.S.). Washington, D.C.: National Academies Press; 2010. NLM ID: 101555711 [Book].Google Scholar
  68. 68.
    Guidance for Industry: Oversight of Clinical Investigations — A Risk-Based Approach to Monitoring CDER Data Standards Program. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm269919.pdf. Accessed 10 Jun 2014
  69. 69.
    Krentz AJ, Morrow L, Hompesch M. Developing new drugs for diabetes and cardiometabolic disorders: a changing paradigm. Drugs. 2012;72(13):1709–11.PubMedCrossRefGoogle Scholar
  70. 70.
    Svensson A. Sponsors viewpoint – the T2DM regulatory guidances and implications for drug development presentation at development of type 2 diabetes mellitus drugs: state-of-the-art cardiovascular safety assessments. October 5–6, 2010 L’Enfant Plaza Hotel, Washington, DC, USA http://www.diahome.org/Tools/Content.aspx?type=eopdf&file=%2fproductfiles%2f23808%2f10035%2Epdf.
  71. 71.
    Braunholtz DA, Edwards SJ, Lilford RJ. Are randomized clinical trials good for us (in the short term)? Evidence for a “trial effect”, J Clin Epidemiol. 2001:54:217–224.Google Scholar

Copyright information

© Springer-Verlag London 2015

Authors and Affiliations

  1. 1.Kinexum Services LLCHarpers FerryUSA

Personalised recommendations